留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

应中央军委要求,2022年9月起,《药学实践杂志》将更名为《药学实践与服务》,双月刊,正文96页;2023年1月起,拟出版月刊,正文64页,数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿!

1例米卡芬净治疗有氟康唑暴露史念珠菌血症的病例分析及相关文献复习

秦又发 张庆 刘莉

秦又发, 张庆, 刘莉. 1例米卡芬净治疗有氟康唑暴露史念珠菌血症的病例分析及相关文献复习[J]. 药学实践与服务, 2016, 34(2): 181-183. doi: 10.3969/j.issn.1006-0111.2016.02.022
引用本文: 秦又发, 张庆, 刘莉. 1例米卡芬净治疗有氟康唑暴露史念珠菌血症的病例分析及相关文献复习[J]. 药学实践与服务, 2016, 34(2): 181-183. doi: 10.3969/j.issn.1006-0111.2016.02.022
QIN Youfa, ZHANG Qing, LIU Li. Clinical analysis of 1 case of micafungin treatment: fluconazole-exposed candidemia and review of related literature[J]. Journal of Pharmaceutical Practice and Service, 2016, 34(2): 181-183. doi: 10.3969/j.issn.1006-0111.2016.02.022
Citation: QIN Youfa, ZHANG Qing, LIU Li. Clinical analysis of 1 case of micafungin treatment: fluconazole-exposed candidemia and review of related literature[J]. Journal of Pharmaceutical Practice and Service, 2016, 34(2): 181-183. doi: 10.3969/j.issn.1006-0111.2016.02.022

1例米卡芬净治疗有氟康唑暴露史念珠菌血症的病例分析及相关文献复习

doi: 10.3969/j.issn.1006-0111.2016.02.022

Clinical analysis of 1 case of micafungin treatment: fluconazole-exposed candidemia and review of related literature

  • 摘要: 目的 探讨临床药师参与有氟康唑暴露史念珠菌血症患者治疗的对策及效果,为临床有效控制此类感染提供参考。 方法 在伏立康唑治疗该病患者效果不佳的情况下,临床药师建议采用米卡芬净抗念珠菌治疗。 结果 患者的念珠菌感染得到有效控制。 结论 米卡芬净能有效治疗近期(<30 d)有氟康唑暴露史的念珠菌血行感染。临床药师参与临床治疗实践,协助制订个体化治疗方案,有利于提高临床药物治疗水平。
  • [1] Pfaller MA, Diekema DJ.Epidemiology of invasive candidiasis:a persistent public health problem[J].Clin Microbiol Rev, 2007, 20(1):133-163.
    [2] Anunnatsiri S, Chetchotisakd P, Mootsikapun P.Fungemia in non-HIV-infected patients:a five-year review.[J].Int J Infect Dis, 2009, 13(1):90-96.
    [3] Playford EG, Lipman J, Sorrell TC.Management of invasive candidiasis in the intensive care unit.[J].Drugs, 2010, 70(7):823-839.
    [4] Pappas PG, Kauffman CA, Andes D,et al.Clinical practice guidelines for the management of candidiasis:2009 update by the Infectious Diseases Society of America.[J].Clin Infect Dis, 2009, 48(5):503-535.
    [5] Ostrosky-Zeichner L, Pappas PG.Invasive candidiasis in the intensive care unit[J].Crit Care Med, 2006, 34(3):857-863.
    [6] Sanford JP. 热病:桑福德抗微生物治疗指南[M].北京:中国协和医科大学出版社,2011:73.
    [7] Prasad PA, Fisher BT, Coffin SE,et al.Pediatric risk factors for candidemia secondary to and species[J].J Pediatric Infect Dis Soc, 2013, 2(3):263-266.
    [8] Shah DN, Yau R, Lasco TM,et al.Impact of prior inappropriate fluconazole dosing on isolation of fluconazole-nonsusceptible Candida species in hospitalized patients with candidemia[J].Antimicrob Agents Chemother, 2012, 56(6):3239-3243.
    [9] Borst A, Raimer MT, Warnock DW,et al.Rapid acquisition of stable azole resistance by candida glabrata isolates obtained before the clinical introduction of fluconazole[J].Antimicrob Agents Chemother, 2005, 49(2):783-787.
    [10] Lortholary O, Desnos-Ollivier M, Sitbon K,et al.Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia:a prospective multicenter study involving 2,441 patients[J].Antimicrob Agents Chemother, 2011, 55(2):532-538.
    [11] Magill SS, Shields C, Sears CL,et al.Triazole cross-resistance among Candida spp.:case report, occurrence among bloodstream isolates, and implications for antifungal therapy[J].J Clin Microbiol, 2006, 44(2):529-535.
    [12] Chang TP, Ho MW, Yang YL,et al.Distribution and drug susceptibilities of Candida species causing candidemia from a medical center in central Taiwan[J].J Infect Chemother, 2013.
    [13] Pfaller MA, Diekema DJ, Ostrosky-Zeichner L,et al.Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin:analysis and proposal for interpretive MIC breakpoints[J].J Clin Microbiol, 2008, 46(8):2620-2629.
    [14] Messer SA, Diekema DJ, Boyken L,et al.Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp.[J].J Clin Microbiol, 2006, 44(2):324-326.
    [15] 胡晶,商洪才,李晶,等.血必净注射液治疗脓毒症的系统评价[J].解放军医学杂志,2010(1):9-12.
  • 加载中
计量
  • 文章访问数:  3049
  • HTML全文浏览量:  317
  • PDF下载量:  10
  • 被引次数: 0
出版历程
  • 收稿日期:  2014-08-02
  • 修回日期:  2015-08-28

1例米卡芬净治疗有氟康唑暴露史念珠菌血症的病例分析及相关文献复习

doi: 10.3969/j.issn.1006-0111.2016.02.022

摘要: 目的 探讨临床药师参与有氟康唑暴露史念珠菌血症患者治疗的对策及效果,为临床有效控制此类感染提供参考。 方法 在伏立康唑治疗该病患者效果不佳的情况下,临床药师建议采用米卡芬净抗念珠菌治疗。 结果 患者的念珠菌感染得到有效控制。 结论 米卡芬净能有效治疗近期(<30 d)有氟康唑暴露史的念珠菌血行感染。临床药师参与临床治疗实践,协助制订个体化治疗方案,有利于提高临床药物治疗水平。

English Abstract

秦又发, 张庆, 刘莉. 1例米卡芬净治疗有氟康唑暴露史念珠菌血症的病例分析及相关文献复习[J]. 药学实践与服务, 2016, 34(2): 181-183. doi: 10.3969/j.issn.1006-0111.2016.02.022
引用本文: 秦又发, 张庆, 刘莉. 1例米卡芬净治疗有氟康唑暴露史念珠菌血症的病例分析及相关文献复习[J]. 药学实践与服务, 2016, 34(2): 181-183. doi: 10.3969/j.issn.1006-0111.2016.02.022
QIN Youfa, ZHANG Qing, LIU Li. Clinical analysis of 1 case of micafungin treatment: fluconazole-exposed candidemia and review of related literature[J]. Journal of Pharmaceutical Practice and Service, 2016, 34(2): 181-183. doi: 10.3969/j.issn.1006-0111.2016.02.022
Citation: QIN Youfa, ZHANG Qing, LIU Li. Clinical analysis of 1 case of micafungin treatment: fluconazole-exposed candidemia and review of related literature[J]. Journal of Pharmaceutical Practice and Service, 2016, 34(2): 181-183. doi: 10.3969/j.issn.1006-0111.2016.02.022
参考文献 (15)

目录

    /

    返回文章
    返回